Try it
Orthopaedics · Paediatric orthopaedics: osteogenesis imperfecta
Sample itemA child with blue sclerae, dentinogenesis imperfecta and recurrent fractures has severe disease. Which drug reduces the fracture rate?
Original practice item, not a recalled exam question. Nothing here is recorded.
The answer and the reasoning
C. Intravenous bisphosphonate
Osteogenesis imperfecta is a defect of type I collagen, and bisphosphonates reduce bone turnover, raise density and reduce fractures. Teriparatide is not used in growing children.
Option by option
A. Teriparatide
Teriparatide is avoided in children with open physes.
B. Calcitriol alone
Calcitriol alone does not correct the collagen defect.
C. Intravenous bisphosphonate (correct)
Correct. Intravenous bisphosphonates are used in severe osteogenesis imperfecta.
D. Growth hormone
Growth hormone has not been shown to reduce fractures.
Source note: Original NextPrep sample item — pending expert review. This item is original practice material awaiting independent expert review, so confirm important facts in a standard textbook.
More Orthopaedics questions
- Upper limb fracturesWhich complication is characteristic of a fracture through the waist of the scaphoid?
- Fractures in childrenA child with a displaced supracondylar fracture of the humerus develops a painful, pale…
- Bone tumoursA teenager has knee pain and a radiograph around the distal femur showing a sunburst per…
- HipA positive Trendelenburg sign is due to weakness of the gluteus medius and minimus. Whic…